Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
Binds the A1 domain of von Willebrand factor and blocks its interaction with platelet glycoprotein Ib, reducing vWF-mediated platelet adhesion and platelet consumption in acquired thrombotic thrombocytopenic purpura.
Indications / reported uses
Treatment of acquired thrombotic thrombocytopenic purpura (aTTP) in adults and paediatric patients aged 12 years and older, in combination with plasma exchange and immunosuppressive therapy; not a substitute for these standard treatments
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Caplacizumab PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Caplacizumab Permitted Daily Exposure (PDE) report (the Caplacizumab PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Caplacizumab Occupational Exposure Limit (OEL) report (the Caplacizumab OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.